---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-044357"
form_type: "8-K"
ticker: "INFU"
cik: "0001337013"
company_name: "InfuSystem Holdings, Inc"
filed_at: "2025-10-06T23:59:59+00:00"
generated_at: "2026-05-17T04:33:33.695006+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# InfuSystem updates TTM revenue to ~$140M, adj EBITDA ~$30M; net leverage 0.86x

## Summary
- TTM 6/30/25 net revenue ~$140M, up from $134.9M in FY2024; adjusted EBITDA ~$30M vs. $25.3M.
- Net leverage 0.86x, debt/equity 0.85x, total available liquidity $49.1M.
- Share repurchase: $7.6M bought under $20M program through June 30, 2025.
- Patient Services gross margin 64.5% TTM; Device Solutions gross margin 39.6% TTM.
- Management estimates FY2025 revenue growth 6-8% and adjusted EBITDA margin >20%.

## SEC filing metadata
- accession: 0001628280-25-044357
- form_type: 8-K
- ticker: INFU
- cik: 0001337013
- company_name: InfuSystem Holdings, Inc
- filed_at: 2025-10-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1337013/000162828025044357/0001628280-25-044357-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1337013/000162828025044357/infu-20251006.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-044357
- JSON: https://secwatch.observer/filing/0001628280-25-044357.json
- Plain text: https://secwatch.observer/filing/0001628280-25-044357.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.